InvestorsHub Logo
Followers 6
Posts 624
Boards Moderated 0
Alias Born 07/14/2015

Re: None

Friday, 08/18/2017 12:21:39 PM

Friday, August 18, 2017 12:21:39 PM

Post# of 34573
We are halfway through the qtr.
3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200
3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer
3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women
with advanced triple-negative breast cancer
4Q 2017: On track to complete enrollment in Phase 2 dosing study of TPIV 200 in TNBC
Year end 2017: File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer.

Come on Glynn give us something........
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News